Community-acquired pneumonia and skin infections: does ceftaroline improve outcomes?

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • Results suggest ceftaroline is a safe and effective therapeutic alternative for patients with community-acquired pneumonia (CAP) or complicated skin and skin structure infections (cSSSI), but it should currently be reserved as an alternative rather than first-line option.

Why this matters

  • Early, widespread use of ceftaroline may promote resistance, and current evidence calls for more conservative conclusions regarding its place in therapy.

Study design

  • Systematic review and meta-analysis comparing efficacy and safety of ceftaroline vs standard antibiotic regimens for CAP and cSSSIs.
  • Funding: None.

Key results

  • 3 randomized controlled trials per indication.
  • Comparator agents: Ceftriaxone in CAP and vancomycin plus aztreonam in cSSSI.
  • In CAP (n=2011), ceftaroline was statistically significantly more efficacious for clinical cure compared to ceftriaxone (risk ratio [RR], 1.11).
  • In cSSSI (n=1496), no statistically significant difference in clinical cure between ceftaroline and comparator regimen (RR, 1.01).
  • No statistically significant difference in mortality for either indication.
  • No major findings for safety outcomes.

Limitations

  • Risk for industry influence was high among studies included in meta-analysis.
  • Possible selective outcome reporting bias.